1. Guan, W.-j., et al., Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 2020.
2. RECOVERY Collaborative Group; P. Horby , W.S.L., J.R. Emberson , M. Mafham , J.L. Bell, L. Linsell, N. Staplin , C. Brightling , A. Ustianowski, E. Elmahi, B. Prudon, C. Green , T. Felton , D. Chadwick , K. Rege, C. Fegan , L.C. Chappell , S.N. Faust , T. Jaki , K. Jeffery , A. Montgomery , K. Rowan , E. Juszczak , J.K. Baillie , R. Haynes , M.J. Landray, Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020. 384(8): p. 693-704.
3. Karampitsakos, T., et al., Increased Red Cell Distribution Width Is Associated With Disease Severity in Hospitalized Adults With SARS-CoV-2 Infection: An Observational Multicentric Study. Front Med (Lausanne), 2020. 7: p. 616292.
4. https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/.
5. Del Valle, D.M., et al., An inflammatory cytokine signature predicts COVID-19 severity and survival. 2020. 26(10): p. 1636-1643.
6. Tanaka, T., M. Narazaki, and T. Kishimoto, IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 2014. 6(10): p. a016295.
7. Pons, S., et al., The vascular endothelium: the cornerstone of organ dysfunction in severe SARS-CoV-2 infection. Crit Care, 2020. 24(1): p. 353.
8. Aziz, M., R. Fatima, and R. Assaly, Elevated interleukin-6 and severe COVID-19: A meta-analysis. J Med Virol, 2020. 92(11): p. 2283-2285.
9. Mehta, P., et al., COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet, 2020. 395(10229): p. 1033-1034.
10. Xu, X. and M. Han, Effective treatment of severe COVID-19 patients with tocilizumab. 2020. 117(20): p. 10970-10975.
11. Yazici, Y., et al., Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Annals of the Rheumatic Diseases, 2012. 71(2): p. 198-205.
12. Si, S. and D.T. Teachey, Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date. 2020. 16: p. 705-714.
13. Karampitsakos, T., et al., Biologic Treatments in Interstitial Lung Diseases. Front Med (Lausanne), 2019. 6: p. 41.
14. RECOVERY, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, 2021. 397(10285): p. 1637-1645.
15. Stone, J.H., et al., Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020. 383(24): p. 2333-2344.
16. Soin, A.S., et al., Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med, 2021. 9(5): p. 511-21.
17. Veiga, V.C., et al., Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ, 2021. 372: p. n84.
18. Salama, C., et al., Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med, 2021. 384(1): p. 20-30.
19. Rosas, I.O., et al., Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. New England Journal of Medicine, 2021. 384(16): p. 1503-1516.
20. Hermine, O., et al., Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine, 2021. 181(1): p. 32-40.
21. Gordon, A.C. and P.R. Mouncey, Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021. 384(16): p. 1491-1502.
22. Salvarani, C., et al., Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Internal Medicine, 2021. 181(1): p. 24-31.
23. WHO, A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis, 2020. 20(8): p. e192-e197.
24. Rahman, S., et al., Bias due to censoring of deaths when calculating extra length of stay for patients acquiring a hospital infection. BMC Med Res Methodol, 2018. 18(1): p. 49.
25. Angriman, F., et al., Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. Lancet Respir Med, 2021. 9(6): p. 655-664.
26. Manson, J.J., et al., COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol, 2020. 2(10): p. e594-e602.
27. Fajgenbaum, D.C. and C.H. June, Cytokine Storm. 2020. 383(23): p. 2255-2273.
28. Sinha, P., et al., Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. Lancet Respir Med, 2020. 8(12): p. 1209-1218.
29. Gu, Y., et al., PaO2/FiO2 and IL-6 are risk factors of mortality for intensive care COVID-19 patients. Scientific Reports, 2021. 11(1): p. 7334.
30. Dorward, D.A. and C.D. Russell, Tissue-Specific Immunopathology in Fatal COVID-19. 2021. 203(2): p. 192-201.
31. Murthy, S. and T.C. Lee, IL-6 blockade for COVID-19: a global scientific call to arms. Lancet Respir Med, 2021. 9(5): p. 438-440.
32. Tomasiewicz, K., et al., Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. 2021. 19(1): p. 93-100.
33. Campochiaro, C., et al., Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med, 2020. 76: p. 43-49.